主要参考资料: 1、《医药行业专题研究:NASH药物,百亿市场下一城》,西南证券,2022-10-08; 2、《NAFLD/NASH全球在研药物情况》,肽研社,2022-10-28; 3、Pfister D, Nú?ez N G, Pinyol R, et al. NASH limitsanti-tumour surveillance in immunotherapy-treated HCC [J]. Nature, 2021; 4、Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH; 5、Pfizer's NASH Treatment Lands FDA Fast Track Designation;Biospace.